Nasdaq:US$18.12 (-0.52) | HKEX:HK$28.85 (+0.10) | AIM:£2.93 (-0.03)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
公告及新聞稿, 監管通知 | 2023-10-24

Vesting of awards under the Long Term Incentive Plan (只備有英文版本)

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, October 24, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on October 20, 2021 to the following persons discharging managerial responsibilities were vested on October 20, 2023:-

 

Award Holder Number of American depositary shares (“ADS”)
Mr Simon To (Executive Director) 1,9381
Dr Dan Eldar (Non-executive Director (“NED”)) 1,938
Ms Edith Shih (NED) 1,9382
Mr Paul Carter (Independent Non-executive Director (“INED”)) 1,6473
Mr Graeme Jack (INED) 1,938
Professor Tony Mok (INED) 1,938

 

Notes:

  1. Similar to the arrangement for his Director’s fees, these ADSs were not received by Mr Simon To, but were received by or for the account of his employer, Hutchison Whampoa (China) Limited.
  2. These ADSs were not received by Ms Edith Shih, but were received by or for the account of her employer, Hutchison International Limited.
  3. Mr Paul Carter elected, on acceptance of the grant of his awards, to have 15% of his LTIP awards (amounting to US$9,375 with respect to his awards which vested on October 20, 2023) held on his behalf by the trustee administering the LTIP pending vesting in the form of cash, to settle his tax liabilities in respect of his awards.

 

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

 

(a) Dr Dan Eldar

 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Dan Eldar
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)

Description of the financial instrument, type of instrument

Identification code

ADS each representing five Ordinary Shares of US$0.10

 

ADS ISIN: US44842L1035

b) Nature of the transaction Vesting of awards granted on October 20, 2021 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 1,938 ADS
d) Aggregated information

Aggregated volume
Price
N/A
e) Date of the transaction 2023-10-20
f) Place of the transaction Outside a trading venue

 

(b) Mr Paul Carter

 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Paul Carter
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)

Description of the financial instrument, type of instrument

 

Identification code

ADS each representing five Ordinary Shares of US$0.10

 

ADS ISIN: US44842L1035

b) Nature of the transaction Vesting of awards granted on October 20, 2021 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 1,647 ADS
d) Aggregated information

Aggregated volume
Price
N/A
e) Date of the transaction 2023-10-20
f) Place of the transaction Outside a trading venue

 

(c) Mr Graeme Jack

 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Graeme Jack
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)

Description of the financial instrument, type of instrument

Identification code

ADS each representing five Ordinary Shares of US$0.10

 

ADS ISIN: US44842L1035

b) Nature of the transaction Vesting of awards granted on October 20, 2021 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 1,938 ADS
d) Aggregated information

Aggregated volume
Price
N/A
e) Date of the transaction 2023-10-20
f) Place of the transaction Outside a trading venue

 

(e) Professor Tony Mok

 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Professor Tony Mok
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)

Description of the financial instrument, type of instrument

 

Identification code

ADS each representing five Ordinary Shares of US$0.10

 

ADS ISIN: US44842L1035

b) Nature of the transaction V Vesting of awards granted on October 20, 2021 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 1,938 ADS
d) Aggregated information

Aggregated volume
Price
N/A
e) Date of the transaction 2023-10-20
f) Place of the transaction Outside a trading venue

 

About HUTCHMED

is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.